↓ Skip to main content

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
7 X users
facebook
1 Facebook page

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration‐Resistant Prostate Cancer
Published in
Oncologist, October 2014
DOI 10.1634/theoncologist.2014-0345
Pubmed ID
Authors
Abstract

Author Summary BACKGROUND: Preclinical studies demonstrated that non-nucleoside reverse transcriptase inhibitors used for the treatment of HIV could antagonize tumor development. This led us to assess the efficacy of efavirenz in patients with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter phase II study.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Spain 1 2%
Unknown 45 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 9 20%
Student > Doctoral Student 5 11%
Student > Bachelor 5 11%
Student > Ph. D. Student 5 11%
Student > Master 3 7%
Other 5 11%
Unknown 14 30%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 8 17%
Biochemistry, Genetics and Molecular Biology 7 15%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Agricultural and Biological Sciences 3 7%
Computer Science 2 4%
Other 5 11%
Unknown 18 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2022.
All research outputs
#10,257,568
of 34,826,706 outputs
Outputs from Oncologist
#2,305
of 4,932 outputs
Outputs of similar age
#90,366
of 308,252 outputs
Outputs of similar age from Oncologist
#17
of 36 outputs
Altmetric has tracked 34,826,706 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 4,932 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,252 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.